Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The site will be located at Sportsmed Biologic in Melbourne, and directed by specialist sports physician Dr Phillip Bloom, who has more than two decades of clinical experience in osteoarthritis management.

This will be the first of 11 Australian sites earmarked for participation in the PARA_OA_012 study. Paradigm has also received informed consent from its first Australian patient, who will take part in the trial.

Alongside the Oz component, there will also be 48 sites in the States that are currently in advanced preparations for activation under the centralised ethics approval.

Managing director Paul Rennie said these were significant milestones for the Paradigm.

“The activation of our first site in Australia and the consenting of our first patients in Australia, with the US soon to follow, mark a significant operational achievement for the company,” Mr Rennie said.

More market news

Forget U.S. tariff talk: Aussies just got a worrying signal from the ABS

Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst

He continued: “I am particularly pleased to see the high level of engagement from leading clinical investigators and trial sites.

“I am also pleased that the company is progressing in line with our intended schedule.”

PAR has been trading at 30.5 cents.

Join the discussion: See what HotCopper users are saying about Paradigm Biopharmaceuticals and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

The addition of the hospital will offer a number of benefits to the trial: Not only expanding its cohort of patients to sample from, but boosting market awareness of the trial and of Cleo – given the Royal Women’s is Australia’s leading specialist hospital for women’s health.

Cleo is also progressing a U.S. clinical trial to facilitate its submission to the Food and Drug Administration (FDA) which is on-track for the 2025 calendar year. Patient recruitment is ongoing across eight sites; an expected 500 people will take part.

Royal Women’s Hospital Director of Oncology Associate Professor Orla McNally said the Australian trial would be a boon for diagnosis of ovarian cancer.

“Early and accurate detection of ovarian cancer is a critical unmet need,” she said.

“Cleo’s ovarian cancer blood test has the potential to better inform clinical workflows for clinicians to ultimately provide better health outcomes for women.

“We are pleased to be working with Cleo Diagnostics on this shared vision.”

Cleo has been trading at 35 cents.

Join the discussion: See what HotCopper users are saying about Cleo and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

The protein, known as FTO (Fatso or FaT and Obesity associated protein), plays a key role in regulating m6A RNA levels, with several cancers being associated with deregulation of this process.

The scientific and pharmaceutical communities are thus strongly interested in the development of FTO-inhibitor drugs due to their potential as cancer treatments.

Race commissioned Monash University’s Fragment Platform (MFP) to conduct an NMR-based fragment screen to identify unique chemical structures which bind to the FTO or ALKBH proteins (the latter being a protein family with similarities to FTO).

From this, 39 new FTO-binding molecules were picked up, with their binding properties confirmed by multiple NMR methods and surface plasmon resonance.

Vice President of Research Professor Mike Kelso said this was a significant milestone for Race.

“Identification of chemical ‘hits’ that bind to a protein target of interest is a critical step in modern drug discovery,” he said.

“Our successful FTO program at Monash provides Race with valuable new IP in the RNA epigenetics space, an enormously exciting area at the cutting-edge of oncology research and drug development.”

Race shares have been higher since the news, and at 11:31 AEDT, they were trading at $1.40 – a rise of 2.94% since the market opened.

Join the discussion: See what HotCopper users are saying about Race and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

Median prices have declined 4.4% in Melbourne and7.6% in the State’s regions since the peak of early 2022, according to the latestCore Logic figures.

Real Estate Institute of Victoria’s Jacob Caine says thefundamentals and long term growth drivers for property remained‘very strong in the Garden State’.

We talk with Mr Caine about the drivers for the Victorian market.

Disclaimer: The information provided by Property Hub does not constitute personal financial/product/investment advice. The information provided is of a general nature only and does not take into account your individual objectives, financial situation or needs. It should not be used, relied upon, or treated as a substitute for specific professional advice. Property Hub recommends that you obtain your own independent professional advice before making any decision in relation to your particular requirements or circumstances. Past performance of any product discussed is not indicative of future performance. We may at times refer to third parties. Details of these third parties have been provided solely for you to obtain further information about other relevant products and entities in the market.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.